New 'armored' CAR produces responses in patients whose cancers don't respond to current CAR T cell therapies

While CAR T cell therapy has revolutionized treatment for many blood cancers, including non-Hodgkin lymphoma (NHL), many patients who receive CAR T cell therapy do not experience a long-term remission. For those whose cancers return or become resistant after CAR T cell therapy, the prognosis is poor, with few options left.

Related Keywords

United States ,American ,Jakub Svoboda ,University Of Pennsylvania ,American Society Of Clinical Oncology ,Perelman School Of Medicine ,Penn Center ,American Society Of Hematology ,Penn Medicine Abramson Cancer Center ,Carl June ,Perelman School ,American Society ,Clinical Oncology ,Annual Meeting ,Penn Medicine ,Abramson Cancer ,Oral Abstract Session ,